U.S. Genomics is pioneering Single Molecule Biology tools for the global life sciences industry. The Trilogy® platform is the first commercially available technology to enable the direct detection and analysis of individual molecules of DNA, RNA, and proteins, without the need for amplification. Combining advances in microfluidics, optical engineering, and novel labeling strategies, the innovative platform allows genetics, functional genomics, and diagnostics to be performed at the single molecule level. The Trilogy platform incorporates instruments and reagents for researchers in academia, contract service organizations, pharmaceutical and biotech industries, as well as healthcare providers. U.S. Genomics’ portfolio of products will further a greater understanding of human genetics and disease pathways and ultimately more effective therapeutics and diagnostics.

Founded in 1997 and based in Woburn, MA, U.S. Genomics has raised a total of $50 million from HealthCare Ventures, StillRiver Fund, CB Health Ventures, Fidelity Biosciences Group, Zero Stage Capital and private investors. Currently, U.S. Genomics has more than 30 scientific collaborations with leading pharmaceutical, biotech, diagnostic and academic research laboratories.